{"analyses":[{"ciLowerLimit":"0.404","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.261","estimateComment":"The hazard ratios were estimated using Cox regression.","groupDescription":"Stratified analysis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9179","paramType":"Hazard Ratio (HR)","paramValue":"0.956","statisticalComment":"The strata were number of prior cancer treatments (1, \\> 1) and β2-microglobulin level (\\< 3.5, ≥ 3.5 mg/L).","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.369","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.893","estimateComment":"The hazard ratios were estimated using Cox regression.","groupDescription":"Unstratified analysis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.6665","pValueComment":"The tests were exploratory because patients were not randomized to the two arms with respect to response status.","paramType":"Hazard Ratio (HR)","paramValue":"0.836","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.86","upperLimit":"8.31","value":"6.0"},{"groupId":"OG001","lowerLimit":"4.73","upperLimit":"11.83","value":"6.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"Duration of response was defined as the time from the initial response to disease progression or death on study. Disease progression was determined by the investigator using the IMWG's uniform response criteria and defined as an increase of ≥25% from best response in: Serum M-protein and/or Urine M-protein and/or Marrow plasma cells; or new or increased plasmacytomas or bone lesions; or hypercalcemia due to myeloma. Duration of response was estimated using Kaplan-Meier. For patients who had not progressed or died, duration of response was censored at the date of the last response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.","id":"OG000","title":"BORT + P"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.","id":"OG001","title":"BORT + BV"}],"paramType":"MEDIAN","populationDescription":"Randomized Patients with an overall response","reportingStatus":"POSTED","timeFrame":"From randomization to the end of study (clinical cut-off; up to 116 weeks).","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}